Newer generation bioprosthetic aortic valves (AV) may confer a hemodynamic advantage over older models. Premarket data suggest that the St. Jude Medical Trifecta AV results in indexed effective orifice areas (EOAi) associated with single-digit mean pressure gradients at 1 year after AV replacement.
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However, real-world hemodynamic performance data and head-to-head comparison against older models such as the Mosaic™ AV are not known.
METHODS
Of 166 patients who underwent AV surgery, 96 patients received a Trifecta AV (mean age 74 years, 47% women, 19 to 25 mm), and 70 patients received a Mosaic AV (Medtronic, Inc, Minneapolis, MN) (mean age 69 years, 31% women, 21 to 29 mm). Table 1 shows the valve size distribution. Transthoracic Doppler echocardiography was performed in all patients after surgery (post-implant to 2 weeks). time integral for both valves was similar. The average velocity ratio was significantly higher for Trifecta AV than for Mosaic AV. There were no cases of severe mismatch in the Trifecta AV group vs. 11% for Mosaic AV (Table 4 ). 
RESULTS
Postoperative average mean and peak AV gradients for Mosaic AV were significantly higher than for Trifecta AV (Table 2) . Mean gradients for the Mosaic AV were twice as high as those for Trifecta AV for valve sizes 21 mm and 23 mm (Table 3) . Left ventricular outflow tract velocity-
CONCLUSIONS
The hemodynamic Doppler indices of the Trifecta AV are outstanding compared to those of the Mosaic AV across all valve sizes with higher VR consistent with low resistance to aortic valve outflow.
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Brief Summary: Please review the Instructions for Use prior to using these devices for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.
Indications:
The Trifecta Valve is indicated as a replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve. Adverse events potentially associated with the use of bioprosthetic heart valves include: angina, cardiac arrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, leak (transvalvular or perivalvular), myocardial infarction, nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other), prosthesis regurgitation, stroke, structural deterioration (calcification, leaflet tear, perforation, or other), thromboembolism and valve thrombosis. It is possible that these complications could lead to reoperation, explantation, permanent disability or death. 
